Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Takanori, Hidaka"'
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Plasminogen activating inhibitor-1 (PAI-1) plays crucial roles in the development of various cancers, including melanomas. Indeed, various pro-tumorigenic functions of PAI-1 in cancer progression and metastasis have been widely reported. Among them,
Externí odkaz:
https://doaj.org/article/f2cdaabb1655498a93333cfcd2e3169c
Autor:
Yota Sato, Taku Fujimura, Takanori Hidaka, Chunbing Lyu, Kayo Tanita, Shigeto Matsushita, Masayuki Yamamoto, Setsuya Aiba
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Aryl hydrocarbon receptor (AhR) provides a deeper insight into the pathogenesis of cutaneous squamous cell carcinoma (cSCC). AhR ligands, such as 6-formylindolo[3,2-b] carbazole (FICZ), and 7,12-Dimethylbenz[a]anthracene (DMBA), constitute major subs
Externí odkaz:
https://doaj.org/article/2a6b5e1d4f0a4fc0968e1f6ee8ab6ad5
Autor:
Kayo Tanita, Taku Fujimura, Yota Sato, Takanori Hidaka, Sadanori Furudate, Yumi Kambayashi, Akira Tsukada, Akira Hashimoto, Setsuya Aiba
Publikováno v:
Case Reports in Oncology, Vol 10, Iss 1, Pp 328-332 (2017)
Acquired ichthyosis (AI) is a reactive cutaneous manifestation that can be associated with malignant hematological disease, including cutaneous T-cell lymphoma (CTCL). Since it is difficult to distinguish AI from ichthyosiform mycosis fungoides, to s
Externí odkaz:
https://doaj.org/article/7f5a0a60cb3b49289be92c0e9f4568a7
Autor:
Sadanori Furudate, Taku Fujimura, Akira Tsukada, Yota Sato, Takanori Hidaka, Kayo Tanita, Yumi Kambayashi, Takahiro Haga, Akira Hashimoto, Setsuya Aiba
Publikováno v:
Case Reports in Oncology, Vol 10, Iss 1, Pp 52-56 (2017)
Primary cutaneous apocrine carcinoma (PCAC) is a rare and highly aggressive cutaneous adnexal type of tumor that has a high metastasis rate and a poor prognosis. Although there are several case reports describing the successful treatment of PCAC with
Externí odkaz:
https://doaj.org/article/2bcce8ac71174a1689aab0f88beffc09
Autor:
Yota Sato, Taku Fujimura, Yumi Kambayashi, Akira Tsukada, Takanori Hidaka, Kayo Tanita, Takahiro Haga, Akira Hashimoto, Setsuya Aiba
Publikováno v:
Case Reports in Oncology, Vol 10, Iss 1, Pp 106-111 (2017)
Both long-term administration of immunosuppressive agents and chronic inflammatory conditions, such as autoimmune disease, could be risk factors for the development of cutaneous squamous cell carcinoma (cSCC). In this report, we present a case of rec
Externí odkaz:
https://doaj.org/article/c60bf438573c480dad43d10eb93a4bc5
Publikováno v:
Frontiers in Medicine, Vol 6 (2019)
The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor that responds to a wide range of chemicals, including chemical carcinogens such as dioxins and carcinogenic polyaromatic hydrocarbons, and induces a battery of genes assoc
Externí odkaz:
https://doaj.org/article/4c47332df2574bd89cef82169ad3c369
Publikováno v:
Frontiers in Medicine, Vol 6 (2019)
Therapeutic options for treating advanced melanoma are progressing rapidly. Although anti-programmed cell death 1 (PD1) antibodies (e.g., nivolumab, pembrolizumab) have been approved as first-line and anchor drugs, respectively, for treating advanced
Externí odkaz:
https://doaj.org/article/2fa9a1954d38409ba295b5dbe35e2a0f
Autor:
Taku Fujimura, Yumi Kambayashi, Yota Sato, Kayo Tanita, Ryo Amagai, Akira Hashimoto, Takanori Hidaka, Setsuya Aiba
Publikováno v:
Frontiers in Medicine, Vol 6 (2019)
Ipilimumab, in combination with nivolumab, is one of the promising drugs that enhance the anti-tumor immune response of patients with advanced melanoma. Since the co-administration of nivolumab with ipilimumab in the neoadjuvant setting expands melan
Externí odkaz:
https://doaj.org/article/0118a4ef51244802af6a0ce53ad11b31
Autor:
Sadanori Furudate, Taku Fujimura, Yumi Kambayashi, Takanori Hidaka, Akira Hashimoto, Setsuya Aiba
Publikováno v:
Case Reports in Oncology, Vol 9, Iss 3, Pp 644-649 (2016)
Since nivolumab significantly prolongs survival in patients with metastatic melanoma, the number of patients administered nivolumab is increasing, but only 30–40% of patients who received nivolumab monotherapy experienced objective tumor regression
Externí odkaz:
https://doaj.org/article/7ac29c9669a542f1ae5b2a563be03488
Autor:
Taku Fujimura, Yota Sato, Kayo Tanita, Yumi Kambayashi, Atsushi Otsuka, Yasuhiro Fujisawa, Koji Yoshino, Shigeto Matsushita, Takeru Funakoshi, Hiroo Hata, Yuki Yamamoto, Hiroshi Uchi, Yumi Nonomura, Ryota Tanaka, Megumi Aoki, Keisuke Imafuku, Hisako Okuhira, Naoko Wada, Hiroyuki Irie, Takanori Hidaka, Akira Hashimoto, Setsuya Aiba
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
Antibodies against programmed cell death protein 1, such as nivolumab and pembrolizumab, are widely used for treating various cancers, including advanced melanoma. Nivolumab significantly prolongs survival in patients with metastatic melanoma, and se
Externí odkaz:
https://doaj.org/article/bd32b94688fe474fb8cbbc50d105f812